(E)-3-(4-tert-butylphenoxy)acrylic acid | 1373443-31-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (E)-3-(4-tert-butylphenoxy)acrylic acid
• 英文别名: (E)-3-(4-tert-butylphenoxy)prop-2-enoic acid
• CAS: 1373443-31-2
• 化学式: C₁₃H₁₆O₃
• 分子量: 220.268
• InChiKey: JNKNXURJDWNNSL-CMDGGOBGSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-氨基苯甲酸甲酯 、 (E)-3-(4-tert-butylphenoxy)acrylic acid 在 N,N-二异丙基乙胺 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以40%的产率得到(E)-3-(3-(4-t-butylphenoxy)acrylamido)benzoic acid methylester
  参考文献：
  名称：

  페녹시아크릴 유도체 및 이의 용도

  摘要：

  这项发明涉及苯氧基乙酰诱导体化合物及其作为有效成分包含在非酒精性脂肪肝预防或治疗药物组合物中的药学组合物。根据本发明，由化合物具有出色的SREBP-1c活性抑制和FAS表达抑制能力，可以预期将其作为预防、改善或治疗非酒精性脂肪肝的药学组合物或功能性食品组合物的活性成分得到有益利用。

  公开号：

  KR20150088205A
• 作为产物：
  描述：

  (E)-3-(4-tert-butylphenoxy)acrylic acid methyl ester 在 lithium hydroxide monohydrate 、 水 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 以11%的产率得到(E)-3-(4-tert-butylphenoxy)acrylic acid
  参考文献：
  名称：

  페녹시아크릴 유도체 및 이의 용도

  摘要：

  这项发明涉及苯氧基乙酰诱导体化合物及其作为有效成分包含在非酒精性脂肪肝预防或治疗药物组合物中的药学组合物。根据本发明，由化合物具有出色的SREBP-1c活性抑制和FAS表达抑制能力，可以预期将其作为预防、改善或治疗非酒精性脂肪肝的药学组合物或功能性食品组合物的活性成分得到有益利用。

  公开号：

  KR20150088205A

文献信息

• ARYLOXY PHENOXY ACRYLIC COMPOUND HAVING HIF-1 INHIBITION ACTIVITY, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS AN ACTIVE INGREDIENT
  申请人：Lee Kyeong

  公开号：US20130237542A1

  公开（公告）日：2013-09-12

  The present invention relates to a compound inhibiting HF-1 activity, a preparation method of the same, and a pharmaceutical composition comprising the same as an active ingredient. The compound of the present invention demonstrates anticancer activity not by non-selective cytotoxicity but by inhibiting the activity of HIF-1, the transcription factor playing an important role in cancer cell growth and metastasis. Accordingly, the compound or the pharmaceutically acceptable salt thereof according to the present invention inhibits HIF-1 activity, and therefore can be used as a therapeutic agent for solid tumors such as colon cancer, liver cancer, stomach cancer and breast cancer. In addition, the compound or the pharmaceutically acceptable salt thereof according to the present invention can be used as an active ingredient for a therapeutic agent for diabetic retinopathy or arthritis which may become worse when hypoxia-induced VEGF expression by HIF-1 increases.

  本发明涉及一种抑制HF-1活性的化合物，以及该化合物的制备方法和包含该化合物作为活性成分的药物组合物。本发明的化合物通过抑制HIF-1活性而不是通过非选择性细胞毒性表现出抗癌活性，HIF-1是在癌细胞生长和转移中起重要作用的转录因子。因此，根据本发明的化合物或其药用盐抑制HIF-1活性，因此可以用作固体肿瘤如结肠癌、肝癌、胃癌和乳腺癌的治疗剂。此外，根据本发明的化合物或其药用盐还可以用作糖尿病视网膜病变或关节炎的治疗剂的活性成分，当HIF-1诱导的VEGF表达增加时，这些疾病可能会恶化。
• 페녹시아크릴 유도체 및 이의 용도
  申请人：Dongguk University Industry-Academic Cooperation Foundation 동국대학교 산학협력단(220060081783) BRN ▼201-82-04468

  公开号：KR20150088205A

  公开（公告）日：2015-07-31

  본 발명은 페녹시아세틸 유도체 화합물 및 이를 유효성분으로 포함하는 비알콜성 지방간 질환의 예방 또는 치료용 약학적 조성물에 관한 것이다. 본 발명에 따른 화합물은 SREBP-1c의 활성 억제 및 FAS 발현 억제능이 우수한바, 비알콜성 지방간 질환을 예방, 개선 또는 치료하기 위한 약학적 조성물 또는 기능성 식품 조성물의 활성성분으로 유용하게 사용될 수 있을 것으로 기대된다.

  这项发明涉及苯氧基乙酰诱导体化合物及其作为有效成分包含在非酒精性脂肪肝预防或治疗药物组合物中的药学组合物。根据本发明，由化合物具有出色的SREBP-1c活性抑制和FAS表达抑制能力，可以预期将其作为预防、改善或治疗非酒精性脂肪肝的药学组合物或功能性食品组合物的活性成分得到有益利用。
• US8940936B2
  申请人：——

  公开号：US8940936B2

  公开（公告）日：2015-01-27
• Synthesis and Structure–Activity Relationship of (<i>E</i>)-Phenoxyacrylic Amide Derivatives as Hypoxia-Inducible Factor (HIF) 1α Inhibitors
  作者：Ravi Naik、Misun Won、Bo-Kyung Kim、Yan Xia、Hyun Kyung Choi、Guanghai Jin、Youngjin Jung、Hwan Mook Kim、Kyeong Lee

  DOI：10.1021/jm301419d

  日期：2012.12.13

  A series of (E)-phenoxyacrylic amide derivatives were synthesized and evaluated as hypoxia inducible factor (HIF) la inhibitors. The present structure activity relationship study on this series identified the morpholinoethyl containing ester 4p as a potent inhibitor of HIF-1 alpha under hypoxic conditions (IC50 = 0.12 mu M in a cell-based HRE reporter assay) in HCT116 cells. The representative compound 4p suppressed hypoxia-induced HIF-1 alpha accumulation and targeted gene expression in a dose-dependent manner. The effect of HIF-l alpha inhibition by 4p was further demonstrated by its inhibitory activity on in vitro tube formation and migration of cells, which may be valuable for development of novel therapeutics for cancer and tumor angiogenesis.